BrainChild Bio
Oncology Therapeutics
4open roles
$115kmedian advertised pay
$116Mlatest round · Series A · Sep 2026 · 2 mo ago
Scaling fasthiring pace, 83 of 100
Overview
BrainChild Bio is a kids-first, clinical-stage biotechnology company harnessing the power of CAR-T cell technology for tumors in the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology platform to adult indications.
Funding and backers
Total raised
$116M
1 round on record
Latest round
$116M
Series A · Sep 2026 · 2 mo ago
Team
40
US Form 5500 (plan participants) · Dec 2025 · +18% in a year
Hiring now
6
+4 posted in 30 days
The money's age
Fresh money
2 months since the last round · and hiring
Momentum
72/100
hiring for its size, a new city, in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 8
Raised a round Series A $116M · Chemical & Engineering News
Oct 1, 2025
Partnership OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer · YahooFinance
Dec 2023
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Sep 2026 | $116M | — | Chemical & Engineering News |
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Eisbach Bio is a clinical-stage biotechnology company developing next-generation cancer therapies with its proprietary ALLOS platform.
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
Avenzo Therapeutics is a clinical-stage biotechnology company that develops next-generation targeted oncology therapies. It was co-founded…
ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), a best-in-class OxPhos inhibitor targeting the…
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Jobs
$100k – $115k per year · Hybrid · Full-Time · 4+ years exp · Bachelor's Degree · Seattle
JMP
Life Sciences
Cell Culture
Design of Experiments
Apply
$90k – $105k per year · Hybrid · Full-Time · 2+ years exp · Bachelor's Degree · Seattle
JMP
Life Sciences
Cell Culture
Design of Experiments
Apply
$190k – $210k per year · Remote (United States) · Full-Time · 10+ years exp · Bachelor's Degree · United States
GCP
Life Sciences
GMP
MedTech
CAPA
Apply
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$115k
Typical range
$105k – $275k
Open positions
5
5
Jobs
Junior
20%
Middle
20%
Senior
40%
Architect
20%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 1 | $105k | $105k |
| Middle | 1 | $115k | $115k |
| Senior | 2 | $195k | $115k – $275k |
| Architect | 1 | $210k | $210k |
Highest paying role
Sr. Director of Finance
$275k
Normalized to USD per year
All salaries at BrainChild Bio
By role, level and city, against the market · 5 jobs with pay
Growth
Hiring Momentum
83/100
Scaling fast
Open positions
6
4 opened / 1 closed in 30 days
Median time-to-fill
63 days
faster than 19% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Operations
29% ▼
Science & Research
29% ▲
Leadership
14% ▲
Finance
14% ▲
Biotech
14% ▼
Activity Timeline
Added Microsoft Excel to stack
Nov 2026
+3 jobs in a week
Oct 2026
Added CAPA to stack
Oct 2026
Added JMP to stack
Oct 2026
Added Design of Experiments to stack
Oct 2026
Added Cell Culture to stack
Oct 2026
Added GMP to stack
Oct 2026
New location: United States
Oct 2026
Financials
Total raised
$116M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2026 | $116M | Details |
Tech stack
Technologies named in job postings at BrainChild Bio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
7
Postings analysed
8
Stack modernity
49/100
Cloud & platforms
GCP
Developer tools
JMP
Microsoft Excel
Practices & domains
GMP
Cell Culture
Design of Experiments
CAPA
Sign in to see how your skills match this stack
Sign In
News
Seattle biotech BrainChild Bio raises $116M to advance CAR T therapy for childhood brain cancer
Seattle biotech BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for DIPG, a rare and deadly brain tumor that primarily affects young children. The company is building on technology developed at Seattle Children's and i
Read more
Report
BrainChild Bio Raises $116 Million Series A And Launches Pivotal Phase 2 CAR T Cell Trial For Pediatric Brain Cancer
BrainChild Bio has raised $116 million in Series A funding to advance its CAR T cell therapies for central nervous system tumors, including a pivotal Phase 2 clinical trial of its lead candidate BCB-276 in diffuse intrinsic pontine glioma. The financing w
Read more
Report
BrainChild Bio Initiates Pivotal Phase 2 Trial for BCB-276 CAR T cell Therapy for DIPG, a Deadly Pediatric Brain Cancer
ILLUMINATE Phase 2 pivotal study will enroll patients at six leading pediatric oncology centers across the U.S.B7-H3-targeted autologous CAR T cel...
Read more
Report
BrainChild Bio targets deadly brain cancer in children with $116M series A
BrainChild Bio's lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.
Read more
Report
BrainChild Bio raises over $100 million to treat kids' cancers with CAR-Ts
Cash will be used for a Phase 2 trial of the company's treatment for diffuse intrinsic pontine glioma
Read more
Report
OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer
OmniaBio Inc., a next generation contract development and manufacturing organization (CDMO) pioneering the manufacturing of cell and gene therapies (CGT) with robotics and artificial intelligence, and BrainChild Bio Inc, a clinical-stage biotechnology com
Read more
Report
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Seattle
Seattle
United States
HQ
Contact Us
4 open roles 4 posted in 90 days 50% engineering 50-200 est. staff $138k Avg Salary
hires for Science & Research, Leadership, Industrial Engineering
1150 Eastlake Ave, Ste 900, Seattle, WA 98109